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PKIS was assembled to include 367 inhibitors designed, developed, and published by  GSK1. Both physical samples 
as well as the selectivity and potency data for PKIS were made publicly available. Compounds were chosen to 
provide broad coverage of the kinome, selecting diversity in chemical scaffolds and avoiding over-representation 
of inhibitors targeting each  kinase1. The composed set was distributed as a physical plate of DMSO stock solutions 
to all interested investigators free of charge. Among other outcomes, collaborators who screened PKIS have iden-
tified starting points for development of chemical probes for understudied kinases and investigated the role of 
particular kinases of interest in signaling via high content phenotypic  assays2–6. The impact of PKIS screening on 
the scientific community is captured by the steady increase in scientific publications since it has been  available7, 8.
The National Institutes of Health (NIH) recently defined a list of proteins labeled as dark/understudied due 
to a lack of research and reagents to characterize their  function8, 9. The IDG program was initiated to stimulate 
exploration of the role of these dark proteins in mediating disease initiation and propagation with the goal of 
providing IDG-related therapeutic  avenues10, 11. One category of IDG proteins is kinases, where a list of 162 dark 
kinases was curated by the NIH and included in the IDG call for applications.
Two kinases on the IDG list, BRSK1 and BRSK2 were recently identified as inhibitors of the oxidative stress 
responsive transcription factor NRF2 (nuclear factor erythroid-2-related factor 2)12. We have reported that 
overexpression of active BRSK1 or BRSK2 downregulates NRF2 protein levels by suppressing protein translation. 
Focused experiments revealed that BRSK2 inhibits MTOR signaling while inducing phosphorylation of AMPK 
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 substrates12. Although overexpression experiments have demonstrated the importance of BRSK2 in cell signal-
ing, to date, there are no reported small molecule inhibitors to characterize BRSK2 function in cells. Therefore, 
identifying compounds that target this kinase can yield instrumental insights into BRSK2 function.
Part of our remit for the IDG program is the creation or identification of cell active chemical tools that enable 
the study of dark kinases. We have taken advantage of public and internal datasets to look for potential inhibi-
tors of IDG kinases. Through analysis of the PKIS data we identified GW296115 as a compound of interest with 
potent biochemical activity against a few kinases (Fig. 1A)1. 
GW296115 is an indolocarbazole that was designed as an inhibitor of platelet-derived growth factor receptor-β 
(PDGFRβ). This compound, also known as 3744 W, was found to inhibit the autophosphorylation of the cyto-
plasmic domain of PDGFR both in vitro  (IC50 = 1.8 ± 0.12 μM) and in insect cells  (IC50 = 2.0 μM)13. Based on its 
activity on PDGFR, GW296115 was included in PKIS and thus screened in the Nanosyn electrophoretic mobility 
shift assay at two concentrations (100 nM and 1 μM). GW296115 inhibited 3 wild type human kinases > 90% 
at 1 μM in the panel of 224 recombinant kinases (Table S1)1. These 3 kinases were also inhibited > 70% at the 
100 nM dose using the same assay format. The originally disclosed targets of GW296115, PDGFRβ and PDGFRα, 
were inhibited 85% and 84%, respectively, at 1 μM. In parallel, PKIS was profiled via thermal shift assay (TSA)14 
against a panel of 68 kinases, of which 32 kinases were in common with the Nanosyn panel. TSA screening, 
which measures the increase in melting temperature (ΔTm) of a kinase when a small molecule inhibitor binds, 
identified 6 kinases with a thermal shift > 7.5 °C at 10 μM dose (Table S1)1. This initial screening of GW296115 
highlighted 4 IDG kinases as inhibited by this scaffold: BRSK1, BRSK2, STK17B/DRAK2, and STK33.
This compound was further profiled in 17 different cancer and normal cell lines to determine whether it 
impacted cell growth when treated at 1 μM for 72 h. GW296115 did not impact cell growth for any of the cell 
lines tested and is considered generally non-toxic to cells (Fig. 1B)15. This data aligns with the data from NCI60 
panel included in the original PKIS publication, which also demonstrated that GW296115 does not impact cell 
growth when profiled against 60 cancer cell  lines1. Here we further explore the target engagement characteristics 
of GW296115 in vitro and in cells and capture its specificity for the CAMK family of kinases.
Results
Biochemical, enzymatic, and cellular profiling of GW296115.  Based on its narrow profile when 
tested in the combined Nanosyn and TSA panels, GW296115 was included in the recently released Kinase 
Chemogenomic Set (KCGS)15. All of the data presented in the Introduction section was collected prior to the 
inclusion of GW296115 in KCGS and everything that follows has been subsequently generated. Since its inclu-
sion in PKIS and more recently KCGS, we have carried out a broader round of screening at DiscoverX. This 




































































































































































































Figure 1.  GW296115 potently inhibits kinases with minimal effect on cell growth. (A) Structure of GW296115. 
(B) GW296115 does not affect cell growth in multiple cell lines. Cell lines in the panel were treated with 1 μM 
GW296115 for 72 h (N = 2) and analyzed using the deep dye drop method. MCF10A and MRC-5 are non-
malignant cell lines. (C) DiscoverX screen identifies 25 kinases with > 90% inhibition and 41 kinases with ≥ 75% 
inhibition at 1 μM of GW296115. Coral was used to make (C): https ://phans tiel-lab.med.unc.edu/CORAL .
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against 403 wild type human kinases at 1 μM using the DiscoverX scanMAX screening platform, which employs 
an active site-directed competition binding assay to quantitatively measure interactions between test compounds 
and  kinases15, 16. GW296115 inhibited 25 kinases > 90% at 1 μM, resulting in a selectivity index  (S10) of 0.062 at 
1 μM (Table S2, Fig. 1C)17. However, GW296115 did not meet our criteria  (S10(1 μM) < 0.04) for follow-up  Kd 
measurement on kinases inhibited > 80% at 1 μM15.
Due to our interest in the activity of GW296115 on several understudied IDG kinases, we collected full 
dose–response curves for all wild type kinases inhibited ≥ 75% in the DiscoverX panel that were offered by Euro-
fins. Having data in orthogonal formats is a powerful way to confirm inhibitory activity and adds rigor to our 
results. Eurofins has kinase enzymatic radiometric assays for 35 of the kinases on this list (Table S2) and a kinase 
enzymatic LANCE assay for one additional kinase (MAP2K5/MEK5). All assays were carried out at the  Km of 
ATP and in dose–response for the radiometric assays (9-point curve in duplicate), while the LANCE assay was 
carried out at a single concentration (10 μM) in duplicate (Table S2, Fig. 2A)18–22. Out of the 35 kinases evaluated, 
6 IDG kinases demonstrated  IC50 < 100 nM in the Eurofins enzymatic assays (Fig. 2B–G).
Our interest in illuminating BRSK2 biology motivated further investigation of the cellular target engagement 
of BRSK2 by GW296115 using our NanoBRET assay. BRSK2 kinase was fused to 19-kDa luciferase (NLuc) at 
its N-terminus (NLuc–BRSK2) which was transiently expressed in HEK293 cells, and then incubated with 
a cell-permeable fluorescent energy transfer probe (tracer)23. Using increasing concentrations of GW296115, 
dose-dependent displacement of tracer was observed, and provided us with an in-cell  IC50 value. Cellular target 
engagement of BRSK2 in live cells was observed with an  IC50 = 107 ± 28 nM, confirming GW296115 is a potent, 
cell active BRSK2 inhibitor (Fig. 3A).
GW296115 inhibits BRSK2-induced phosphorylation in cells.  With confirmed cellular activity, we 
next focused on characterizing the pathways mediated by BRSK2 utilizing GW296115. BRSK2 has a similar 
kinase domain to AMPK and is activated by LKB1-mediated phosphorylation in the active site at  T17424–26. As 
previously reported, BRSK2 induces phosphorylation of AMPK  substrates12. Therefore, we asked whether this 
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Figure 2.  Dose–response kinase enzymatic activity assays on 35 kinases treated with GW296115 reveal its 
biochemical potency. (A) Heatmap of % kinase activity with 9-point dose response to GW296115, plotted in 
descending order of  IC50 values from Eurofins screen (N = 2). (B–G) Dose response curves for IDG kinases 
with  IC50 < 100 (N = 2): DRAK2  (IC50 = 5.5 nM), BRSK2  (IC50 = 8.4 nM), PHKG1  (IC50 = 20 nM), BRSK1 
 (IC50 = 21 nM), DRAK1  (IC50 = 28 nM), and DCAMKL3  (IC50 = 89 nM), respectively. Python version 3.8 was 
used to make heatmap in (A).
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GW296115 on AMPK substrate phosphorylation in HEK293T cells overexpressing wild-type or kinase-dead 
BRSK2 (Fig. 3B). Specifically, we overexpressed two different kinase-dead BRSK2 constructs, K48A and T174A, 
and treated cells with 2.5 μM of GW296115 for 2 or 6 h. Compared to cells expressing hcRED control, wild-
type BRSK2 overexpression induced AMPK substrate phosphorylation, as measured by phospho-S/T AMPK 
substrate antibody. This change was not observed when overexpressing kinase-dead variants. BRSK2-induced 
AMPK substrate phosphorylation was ablated with GW269115 treatment at both 2- and 6-h time-points. More-
over, we used an antibody against pAMPK T172, a known LKB1 target site, and found that phosphorylation 
at T172 was not altered. However, using the same antibody we were able to detect phosphorylation of BRSK2 
at T174, which showed hyper-phosphorylation in response to GW269115 in all samples except BRSK2 T174A 
expressing cells.
Next we evaluated whether specific bona fide AMPK substrates were phosphorylated by BRSK2. Based on the 
total pS/T AMPK substrate blots, we decided to check known substrates that match the size of the most robust 
changes due to BRSK2 overexpression. UNC51-like kinase 1 (ULK1) is a 120 kDa kinase that is member of the 
autophagy initiation complex, and is phosphorylated by AMPK at multiple residues, S317 and S555, among 
 others27–29. Therefore, we overexpressed wild type BRSK2 in HEK293T cells and measured changes in pULK1 
S317 and S555 following treatment with increasing doses of GW296115 for 2 h. BRSK2 overexpression increased 
phosphorylation of ULK1 at S317, but not S555. BRSK2-induced phosphorylation of ULK1 S317 was decreased 
dose-dependently by GW296115 (Fig. 4A,B). Total AMPK levels remained unchanged and western blots using 
pAMPK T172 showed increased levels of pBRSK2 T174, but the levels of AMPK phosphorylation were not dis-
cernable due to masking by BRSK2 overexpression (Fig. 4A). However, in samples expressing control hcRED, 
treatment with GW296115 increased pAMPK T172. We also asked if activating phosphorylation of ULK1 leads 
to increased phosphorylation of downstream components of the autophagy complex. Therefore we evaluated 
phosphorylation of S351 on P62 (SQSTM1), which is a stress induced autophagy receptor for ubiquitylated 
 cargo30. Due to its central role as a signaling hub, P62 accumulation and phosphorylation serves as a sensor for 
starvation, oxidative stress, and selective  autophagy30–32. Following BRSK2 overexpression, we observed increased 
pP62 S351, which is dose dependently downregulated by GW296115 (Fig. 4A,C). The total P62 expression level 
was not significantly altered in response to GW296115. Overall, these data show that BRSK2 induced AMPK 
substrate phosphorylation including ULK1 and the downstream autophagy effector P62. Moreover, these phos-
phorylation events were ablated by GW296115 in a dose dependent manner (Fig. 4B,C).
Cellular target engagement of BRSK2 by structural analogs of GW296115.  Finally, to inform 
future analog design, we selected a panel of structurally related indolocarbazoles and bisindolylmaleimides to 
profile in the BRSK2 NanoBRET assay (Structures in Fig. 5A, NanoBRET data in Fig. 5B). Kinome-wide selectiv-
ity as well as biochemical potency on BRSK2 and related CAMK family kinases has been published for all except 
Arcyriaflavin A and K-252c33, 34. In those cases where broad kinase screening data was available in the literature, 
we calculated the  S10 selectivity scores corresponding to the percentage of kinases inhibited > 90% at the con-











































































Figure 3.  GW296115 inhibits BRSK2 in cell-based assays. (A) GW296115 engages BRSK2 in cells with 
an  IC50 = 107 ± 28 nM. HEK293 cells were transiently transfected with NLuc-BRSK2 and GW296115 target 
engagement was calculated by measuring the dose-dependent displacement of the tracer (N = 3). (B) GW296115 
inhibits kinase active BRSK2 and downregulates AMPK substrate phosphorylation. HEK293T cells transiently 
expressing hcRED, wild type (WT), or kinase dead (K48A & T174A) were treated with 2.5 μM of GW296115 for 
2 or 6 h. Unformatted images of blots are included in Fig. S2.
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the average of two replicates shown as percent remaining kinase activity in the presence of 0.5 μM compound 
relative to solvent control is shown for each CAMK kinase (Fig.  5D)18–22, 33. Although the assay formats are 
different, including the concentration of compound added and the protein constructs employed, our profiling 
of GW296115 is included for comparison purposes (% control at 1 μM) (Fig. 5D). Given its weak biochemical 
inhibition of BRSK2, bisindolylmaleimide IV was excluded from testing in the NanoBRET assay. Bisindolyl-
maleimide I and Gö 6983, like bisindolylmaleimide IV, are highly UV active compounds and their UV absorb-
ance interfered with the NanoBRET assay readout. With the exception of SB 218078, the rank order in terms 
of biochemical potency and cellular target engagement of BRSK2 by the compounds tracked (Fig. 5B, S1). For 
some, biochemical and cellular potency matched well, while for others there was a modest loss in potency when 
moving into cells. We were able to confirm that structurally related compounds, Arcyriaflavin A and K-252c, for 
which BRSK2 biochemical inhibition data was not found, engage BRSK2 in cells. The BRSK2 NanoBRET data 
supports that indolocarbazoles and bisindolylmaleimides enter cells and potently engage with BRSK2. Overall, 
these data support that GW296115 is the most selective of the potent and cell-active indolocarbazole and bisin-
dolylmaleimide BRSK2 inhibitors profiled.
Structural analyses  to characterize GW296115 binding  to  the CAMK  family of kinases.  To 
rationalize why certain kinases respond differently to these structurally related compounds, we can examine key 
residues in the respective binding pockets and use co-crystal structures. Looking across residues important for 
binding, we see a great deal of conservation within the CAMK kinases inhibited by GW296115 (Fig. 5C). The 
residues that are highlighted in Fig. 5C have been identified via a survey of the entire human kinome as those 
that make essential interactions with a ligand and define the active site in which it binds. All CAMK kinases that 
are listed are compared to BRSK2 and conserved residues are highlighted in green. While CHEK1 was inhibited 
70% at 1 μM by GW296115 (Fig. 5D), it is included because the structure of related compound, SB 218078, 
was solved and published with the CHEK1 kinase domain (PDB: 1NVS) and thus its homology with other 
CAMK family members is  relevant35. SB 218078, like staurosporine, is a potent CHEK1 inhibitor. SB 218078 
and GW296115 both bear a C7 carbonyl that is not present in staurosporine and both lack an elaborated ring 
system like that in staurosporine. Given enhanced structural similarity between SB 218078 and GW296115, the 

































































Figure 4.  GW296115 dose-dependently inhibits BRSK2-induced phosphorylation. (A) BRSK2 overexpression 
induced pULK1 S317, pP62 S351, and pS/T AMPK substrates are decreased dose-dependently by GW296115. 
HEK293T cells were transiently transfected with hcRED or BRSK2 for 24 h before GW296115 treatment for 2 h. 
Unformatted images of blots are included in Fig. S2. (B,C) Western blot quantitation for pULK1 s317 and pP62 
S351 treated with DMSO or GW296115 at 3.4 μM shows statistically significant changes (N = 3).
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GW296115 could be making with homologous CAMK kinases. While both SB 218078 and staurosporine were 
found to bind in the same pocket, the side-chain conformations of residues  E91,  F93,  E134,  S147, and  D148 varied 
between the two structures and SB 218078 was found to make no direct contacts with  E91 and  E134 (Fig. 5C). 
This finding supports that a ring system connecting nitrogens N12 and N13, like that found in staurosporine, 
is able to make favorable interactions with the binding pocket in many kinases, increasing binding affinity and 
inhibition potential. Furthermore,  E91 and  E134 have been characterized as defining the sugar pocket when ATP 
binds (Fig. 5C), supporting that the N12–N13 ring system on staurosporine fits into the same pocket as the 
sugar on ATP. The maleimide of SB 218078 makes hydrogen-bonding interactions with the backbones of  E85 and 
 C87, two residues that have been characterized as making key hydrogen bonds with the hinge-binding part of 
the molecule (Fig. 5C). Compared with staurosporine, SB 218078 was found to shift slightly outward from the 




































































































































































































































































CHEK2 L A C V A K E I L I I L E L M E G G E F D K E N L T D F
STK17B/DRAK2 L K F V A K E I L I L L E Y A A G G E F S K Q N L V D F
BRSK2 L Q T V A K E I L L L L E H V S G G E F D K E N L A D F
PIM2 L G F V A K E V L I V E R P L P A Q D F D K E N I I D F
RPS6KA3/RSK2 I S Y C A K E I L I V T E L M K G G E L D K S N L C D F
RPS6KA6/RSK4 I S Y C A K E I L I L T D L M K G G E L D K S N L C D F
NUAK1/ARK5 L T Y V A K E I M I I M E Y A S K G E Y D K E N I A D F
PHKG1 L V S V A K E V L I L F D L M K R G E F D K E N L T D F
DAPK2 L Q F V A K E V L I L L E L V S G G E F D K E N M I D F
BRSK1 L Q T V A K E I L L L L E H V S G G E F D K E N L A D F
STK17A/DRAK1 L K F V A K E I L I L L E Y A A G G E F D K Q N L V D F
MYLK/MLCK/smMLCK L K F V A K E I M V M L E I V S G G E F E K E N M I D F
PIM3 L G F V A K E V L I V E R P E P A Q D F D K E N L I D F
DCLK3/DCAMKL3 I N F V A K E I I V L L E Y V Q G G D F D K E N L A D F
DAPK3/ZIPK L Q F V A K E V L I L L E L V S G G E F D K E N M I D F
STK33 L S F V A K E V L I L M E L C E D G E K E K E N M T D F
CHEK1 L A Y V A K E I N V L L E Y C S G G E F D K E N L S D F


























































**Compound UV absorbance interfered with assay readout
Compound Selectivity BRSK2 NanoBRET data IC50
(nM)
S10(0.5 µM) = 0.637
191 kinases >90%I
K-252a S10(0.5 µM) = 0.350
105 kinases >90%I
20.2 ± 1.5
S10(0.5 µM) = 0.130
39 kinases >90%I
S10(0.5 µM) = 0.223
67 kinases >90%I
S10(1 µM) = 0.062
25 kinases >90%I
S10(0.5 µM) = 0
0 kinases >90%I
S10(0.5 µM) = 0.043
13 kinases >90%I
S10(0.5 µM) = 0.027
8 kinases >90%I
Arcyriaflavin A NT 7680 ± 3500
S10(0.5 µM) = 0.013
4 kinases >90%I
S10(0.5 µM) = 0.133
40 kinases >90%I
K-252c NT 308 ± 250
Gö 6983 **
CDK4 inhibitor 1330 ± 230
Gö 6976 914 ± 640




Staurosporine 2.22 ± 0.3
Midostaurin 88.9 ± 8
SB 218078 883 ± 200
Figure 5.  Structural- and activity-based comparisons of GW296115 to related compounds. (A) Structures 
of staurosporine, K-252a, midostaurin, SB 218078, bisindolylmaleimide IV, bisindolylmaleimide I, Gö 6983, 
Arcyriaflavin A, CDK4 inhibitor, Gö 6976, and K-252c versus GW296115. (B) Selectivity of compounds shown 
in panel A when profiled against 300 (staurosporine, K-252a, midostaurin, SB 218078, bisindolylmaleimide IV, 
bisindolylmaleimide I, Gö 6983, CDK4 inhibitor, and Gö 6976) or 403 (GW296115) wild type human kinases 
and NanoBRET data for most inhibitors in panel A (N = 3). (C) Alignment of key residues corresponding to 
CAMK kinases potently inhibited by GW296115 and CHEK1. Residues colored green demonstrate homology 
shared with BRSK2 and residue numbers listed below correspond with those discussed with respect to SB 
218078 binding to CHEK1 (also boxed). (D) Inhibition data corresponding with those CAMK kinases (and 
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residue). Based on the binding orientation of SB 218078 to CHEK1, with the N12-N13 ring system oriented 
toward  S147 and  D148, it is likely that these residues are too far away to make key interactions with GW296115 
upon  binding35. Loss of these interactions when GW296115 binds to CHEK1 is proposed to result in its loss of 
affinity for CHEK1 versus SB 218078 and staurosporine (Fig. 5D).
Through analysis of the binding of SB 218078 to CHEK1, we have identified several putative interactions 
that GW296115 makes with CAMK kinases, which share many highly conserved residues. IDG kinases that are 
potently inhibited by GW296115 (BRSK1, BRSK2, DRAK1, and DRAK2) share common features of their binding 
pocket, which include a polar/charged residue (Q or K) within the glycine-rich loop and aliphatic residues at 
positions 87 and 147 (V or A). This pattern is unique to these kinases amongst the larger CAMK kinases inhib-
ited by GW296115. The DAPKs, which are the most homologous kinases to DRAK1 and DRAK2, and NUAK1, 
which is among the most homologous kinases to BRSK1 and BRSK2, show overlap in several, but not all of these 
residues (Fig. 5C). Based on the co-crystal structures of SB 218078 and staurosporine bound to CHEK1, we know 
that positions 87 and 147 make key interactions when this class of molecules are  bound35. When comparing the 
sequence of CHEK1, which is less potently inhibited by GW296115, with those CAMK family members more 
potently inhibited, it appears that the back pocket residues in addition to residue 147 are most different. CHEK1 
has an arginine in the back pocket on the C-helix and a serine at residue 147. An overlapping residue at these 
two positions is not found when surveying those CAMK kinases potently inhibited by GW296115 (Fig. 5C). 
This finding once again points to the inner hydrophobic residue in the pocket that binds the purine core of ATP 
(147) as making key interactions and potentially dictating binding affinity. Further, the co-crystal structures 
support that the side-chain conformation of residue 147 varies between  structures35. Through taking advantage 
of differences in key residues within the binding pocket, we can design molecules that are more selective for 
subfamilies or even specific kinases of interest.
Discussion
The publicly available PKIS library provides a platform to identify tool compounds for a number of kinases, 
including the 162 kinases categorized as understudied in the NIH IDG effort. Developing better reagents to 
evaluate these kinases will help define poorly characterized signaling networks. Here, we show that GW296115 
is a potent inhibitor of several understudied kinases. GW296115 was included in the recently released KCGS 
based on profiling against 260 human kinases. The broader round of screening carried out at DiscoverX included 
403 wild type human kinases. More comprehensive profiling revealed GW296115 to be much less selective than 
the original data suggested. The difference in selectivity observed between the Nanosyn and DiscoverX panels 
highlights the value of utilizing multiple orthogonal assay formats to assess compounds and problems that can 
arise if too much emphasis is placed on one readout.
Although broader screening reveals that GW296115 is less selective than originally thought, it is selective 
enough to have utility. It is worth noting that inhibition of several kinases can elicit polypharmacology and has 
been exploited to develop kinase drugs for cancer. Bosutinib, ponatinib, sunitinib, cabozantinib, and dasatinib 
are some examples of FDA-approved kinase inhibitors that are less selective than GW296115, with  S10(1 μM) 
scores of > 0.15 when tested against 305–311 kinases at 1 μM36. These 5 drugs approved for clinical use were 
profiled using a combination of mobility shift assays and ELISA technology, keeping the ATP concentration 
within twofold of the  Km of ATP for every individual  kinase36. While the methods used to profile GW296115 
and these drugs vary, as do the size of kinase panels, it is clear that kinome-wide selectivity of kinase-targeting 
compounds is not the only determinant in assessing their utility.
To ascertain selectivity of GW296115 and validate our DiscoverX screening results using an orthogonal assay 
format, we chose to utilize Eurofins enzymatic kinase assays in dose–response at the  Km of ATP. We found that 
25 kinases that were profiled at Eurofins exhibited an  IC50 < 150 nM, where 8 kinases had  IC50 ≤ 10 nM (Fig. 6)17, 
37. Importantly, 6 kinases with an  IC50 < 100 nM are IDG dark kinases (RIOK3, also dark, was not tested at 
Eurofins). The 4 IDG kinases identified via Nanosyn and TSA screening (BRSK1, BRSK2, STK17B/DRAK2, and 
STK33) were once again captured in the DiscoverX profiling and confirmed as potently inhibited by GW296115 
at Eurofins. In fact, 8 of 9 kinases from Table S1 were also inhibited ≥ 75% at DiscoverX. PRKAA2 is the outlier 
as treatment with GW296115 at 1 μM resulted in 20% inhibition in the DiscoverX scanMAX panel. Comparison 
of Tables S1 and S2 once again demonstrates the power of using orthogonal assay formats for data generation to 
identify overlapping data and discern possible misleading hits.
Building on the biochemical data generated for GW296115, we carried out studies to determine whether this 
compound was active in cells. Given its confirmed potency against BRSK1/2 in the Nanosyn, DiscoverX, and 
Eurofins panels and our interest in these dark kinases, we first looked to evaluate GW296115 for cellular target 
engagement and pathways regulated by BRSK2. Utilizing BRSK2 NanoBRET assay we confirmed that GW296115 
permeates live cells and exhibits potent engagement of BRSK2 with an  IC50 = 107 ± 28 nM.
With confirmed cell activity, we moved to cell-based experiments to probe how this compound impacts 
BRSK2-mediated pathways. GW296115 inhibited phosphorylation of AMPK substrates in BRSK2-overexpressing 
HEK293T cells. Moreover, this effect was observed after just 2 h of treatment. This finding confirms GW296115 
as a cell-active tool that interrupts a phosphorylation events driven by BRSK2. While GW296115 did not inhibit 
phosphorylation at the LKB1 target site (T172) on AMPK, BRSK2 was hyper-phosphorylated on T174 in response 
to GW296115. BRSK2 T174 hyper-phosphorylation was more notable when overexpressing wild-type BRSK2 
but was also observed when overexpressing K48A BRSK2. This later observation supports that GW296115 may 
result in activation of a compensatory mechanism that induces hyper-phosphorylation when BRSK2 is inhib-
ited, possibly through activation of feedback loops. Further probing of well-defined AMPK substrate ULK1 and 
downstream effector P62 demonstrated that GW296115 inhibited BRSK2-induced phosphorylation in HEK293T 
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cells in a dose-dependent manner. These observations establish that GW296115 can be used to study BRSK2-
mediated pathways in cells.
Stemming from interest surrounding the natural product staurosporine, a plethora of chemistry has centered 
on the bisindolylmaleimide scaffold. Staurosporine (Fig. 5A) is one of the most potent and non-selective kinase 
inhibitors known. Analogs have been designed to reduce the structural complexity of the natural product while, 
at the same time, decrease the number of kinases it potently inhibits. Exemplars in Fig. 5A, like GW296115, bear 
a maleimide to adjoin the two indole ring systems. All inhibitors, with the exception of Arcyriaflavin A, K-252c, 
and GW296115, were profiled against a panel of 300 recombinant protein kinases at 0.5 μM. These were 9 of 
the 178 commercially available kinase inhibitors included in this study by Anastassiadis et al.33. Staurosporine, 
K-252a, and SB 218078 were found to be the top 3 most promiscuous of all compounds tested, respectively 
(Fig. 5B). Through examination of structure versus selectivity, we can clearly see that the bisindolylmaleimide 
scaffold is tunable. Removal of the carbon–carbon bond between C12a and C12b results in great losses in potency 
across the kinome, suggesting that free rotation of the two indole ring systems is not well tolerated by many 
kinases and may prevent bisindolylmaleimides IV and I as well as Gö 6983 from making key interactions with 
the ATP binding site. Addition of the C-7 carbonyl is also tolerated by some kinases but not others. The ring 
system that connects nitrogens N12 and N13 seems to make favorable interactions with kinase binding sites such 
that more kinases are potently inhibited by inhibitors that have it (staurosporine, K-252a, and SB 218078) versus 
those that do not (GW296115 and CDK4 inhibitor, for example). The pocket that binds this N12–N13 ring in 
many kinases, however, does not tolerate too much bulk, so midostaurin with its N-benzoyl group likely results 
in unfavorable steric clash. N-alkylation of the indolyl nitrogens is done to attempt to access binding interactions 
with the part of the pocket that accommodates this N12–N13 ring and the sugar on ATP. Finally, substitution at 
C3, C9, and/or C10 also impacts the number of kinases potently inhibited by bisindolylmaleimides/indolocar-
bazoles. This finding is likely due to the steric clash introduced by these groups with binding pocket residues, 
which is tolerated by some kinases but prevents binding to others.
Our screening data generated around GW296115 demonstrates that the CAMK family of kinases is par-
ticularly sensitive to this compound and many members are potently inhibited by it. The majority of kinases 






















































Figure 6.  Enzymatic assay profile of GW296115. CORAL kinome tree representing kinases inhibited by 
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(Table S2, Fig. 6). These CAMK family kinases are listed from most to least potently inhibited by GW296115 in 
Fig. 5C. When Anastassiadis and co-workers profiled their 178 commercial inhibitors, several of these CAMK 
family members were included in the 300-kinase panel. The same trend was observed within the CAMK family 
as when overall selectivity was calculated (Fig. 5B): the most CAMK kinases were inhibited by staurosporine and 
the least by bisindolylmaleimide IV (Fig. 5D)33. As discussed above, certain CAMK kinases are more sensitive 
to structural changes than others. RSK2 and RSK4, for example, are potently inhibited by all but bisindolylma-
leimide IV and CDK4 inhibitor. In contrast, the DAPK2 ATP binding site is very sensitive to structural changes, 
which is evident when considering inhibition data for staurosporine versus closely related K-252a.
All structurally related indolocarbazoles and bisindolylmaleimides with the exception of bisindolylmaleimide 
IV were tested in the BRSK2 NanoBRET assay to evaluate their cellular target engagement of BRSK2 in live cells 
(Fig. 5A). While bisindolylmaleimide IV was excluded due to its weak biochemical potency on BRSK2, it is also 
highly UV active. Bisindolylmaleimide I and Gö 6983 are two additional highly UV active compounds in the 
series. Testing all 3 compounds using the NanoBRET format was confounded by the high UV absorbance, which 
interfered with the assay at high concentrations (Fig. S1). When we compare the NanoBRET data (Fig. 5B) with 
the biochemical data (Fig. 5D), we observe the same potency trend for compounds included in both panels with 
the exception of SB 218,078. For staurosporine, K-252a, and midostaurin, potent inhibition in an enzymatic 
assay translated to low nanomolar engagement of BRSK2 in the NanoBRET assay  (IC50 < 100 nM). While these 
compounds were more active than GW296115 in the BRSK2 NanoBRET assay, they are much less selective than 
GW296115 when profiled broadly (Fig. 5B). Interestingly, K-252c, for which reported biochemical BRSK2 data 
was not published, was found to engage BRSK2 with an  IC50 = 308 ± 250 nM. Arcyriaflavin A, which was also 
devoid of BRSK2 biochemical data in the literature and only differs from K-252c at the C-7 position, was found 
to be much less active  (IC50 = 7680 ± 3500). Like the remainder of the compounds tested in the BRSK2 NanoBRET 
assay that seem like outliers and have  IC50 values in the 600–1600 nM range (SB 218078, Gö 6976, CDK4 inhibi-
tor), Arcyriaflavin A suffers from poor solubility in DMSO, poor cell penetrance, and/or UV interference in the 
NanoBRET assay. A combination of these factors explain the poor translation of biochemical activity to cell-based 
potency. The BRSK2 NanoBRET data indicates that GW296115 and related structures can enter cells and bind to 
BRSK2, but that compound solubility and/or cell penetrance is a challenge that must be overcome with design.
These structure-based observations and corresponding inhibition data around GW296115 and related bisin-
dolylmaleimides/indolocarbazole support the idea that these scaffolds can be tuned to improve kinome-wide 
selectivity. Kinases are clearly sensitive to specific modifications within these scaffolds. The dataset shown in Fig. 5 
supports GW296115 as the most potent and selective, cell-active inhibitor of BRSK2 within the structural class.
conclusions
GW296115 represents a potent, cell active chemical starting point from which we can design inhibitors. The 
promiscuity of this compound is clearly a feature we can exploit. Among the kinases that were potently inhib-
ited in corresponding enzymatic assays are BRSK1  (IC50 = 21 nM), BRSK2  (IC50 = 8.4 nM) and near neighbor 
(based on homology) NUAK1  (IC50 = 15 nM). The biochemical potency of this compound translates in cells, as 
it demonstrated activity in both the NanoBRET and in cell assays for BRSK2-mediated phosphorylation. While 
GW296115 cannot be considered selective, it is the best available chemical tool to study BRSK1/2 biology.
Materials and methods
Kinome screening. The scanMAX assays were performed at Eurofins DiscoverX Corporation as previously 
 described16.
in vitro kinase radiometric and LAnce assays. Eurofins kinase enzymatic radiometric assays were 
carried out at the  Km of ATP in dose–response (9-pt curve in duplicate) for each kinase for which it was offered. 
Eurofins kinase enzymatic LANCE assay was carried out at the  Km of ATP for MAP2K5/MEK5 at a single con-
centration (10 μM) in duplicate.
cell culture. HEK293 and HEK293T cells were acquired from the American Type Culture Collection 
(ATCC) and then cultured in a humidified incubator at 37 °C and 5%  CO2. Cells were passaged regularly using 
0.05% Trypsin/0.53 mM EDTA in Sodium Bicarbonate (Corning, 25-052-CI), and maintained in Dulbecco’s 
Modified Eagle Medium (DMEM) (Corning, 10–013-CV) supplemented with 10% fetal bovine serum (FBS). 
Analogous cell culture conditions have been previously employed by our  groups12, 38.
nanoBRet measurements. NanoBRET assays were executed as described  previously38. Constructs for 
BRSK2 NanoBRET measurements were provided in kind by Promega. The N-terminal Nanoluciferase (NL)/
BRSK2 fusion (NL-BRSK2) was encoded in pFN32K expression vector, including flexible Gly-Ser-Ser-Gly link-
ers between NL and BRSK2 (Promega). For cellular BRSK2 NanoBRET target engagement experiments, a 10 μg/
mL solution of DNA in Opti-MEM without serum (Gibco) was prepared with 9 μg/mL of Carrier DNA (Pro-
mega) and 1 μg/mL of NL-BRSK2 to achieve a total volume of 1.05 mL. To this solution was then added 31.5 μL 
of FuGENE HD (Promega) to form a lipid:DNA complex, mixed by inversion 8 times, and incubated at room 
temperature for 20 min. The resulting transfection complex (1.082 mL) was next gently mixed with HEK293 
cells (21 mL) suspended at a density of 2 × 105 cells/mL in DMEM containing 10% FBS. Finally, 100 μL of this 
solution was then dispensed into each well of a 96-well tissue culture treated plate (Corning, 3917), and the plate 
was incubated at 37 °C with 5%  CO2 for 24 h.
After 24 h, media was removed via aspiration and 85 μL of room temperature Opti-MEM without phenol red 
(Gibco) was added to each well. NanoBRET Tracer K5 (Promega) was used at a final concentration of 1 μM, the 
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concentration previously determined to be optimal via a tracer titration experiment. Next, 5 μL (20 × working 
stock of NanoBRET Tracer K5 [20 μM] in Tracer Dilution Buffer (Promega N291B)) was added to each well 
with the exception of the “no tracer” control wells. Test compounds were prepared as concentrated stock solu-
tions in 100% DMSO (Sigma) at a concentration of 10 mM. They were then diluted in Opti-MEM media (99%) 
to prepare stock solutions containing 1% DMSO. A volume of 10 μL of tenfold test compound stock solutions 
(final assay concentration of 0.1% DMSO) was added to each well. For “no compound” and “no tracer” control 
wells, 10 μL of Opti-MEM plus DMSO (9 μL Opti-MEM plus 1 μL DMSO) was added to each well to achieve 
a final concentration of 1% DMSO. The resultant 96-well plates containing transfected cells with NanoBRET 
Tracer K5 and test compounds (100 μL total volume per well) were equilibrated at 37 °C with 5%  CO2 for 2 h.
After 2 h, plates were returned to room temperature over the course of 15 min. To measure NanoBRET sig-
nal, a 3 × stock solution was prepared by mixing NanoBRET NanoGlo substrate (Promega) at a ratio of 1:166 to 
Opti-MEM media in combination with extracellular NanoLuc Inhibitor (Promega) diluted 1:500 (10 μL [30 mM 
stock] per 5 mL Opti-MEM plus substrate). Next, 50 μL of the 3 × substrate/extracellular NL inhibitor stock was 
added to each well. Finally, plates were read within 10 min of this addition using a GloMax Discover luminometer 
(Promega) equipped with 450 nm BP filter (donor) and 600 nm LP filter (acceptor), using 0.3 s integration time 
according to the “NanoBRET 618” protocol (Promega).
Test compounds were evaluated at 8 concentrations in competition with NanoBRET Tracer K5 in HEK293 
cells transiently expressing the NL-BRSK2 fusion protein. Raw milliBRET (mBRET) values were obtained by 
dividing the acceptor emission values (600 nm) by the donor emission values (450 nm), and then multiplying by 
1000. Averaged control values were used to represent complete inhibition (no tracer control: transfected cells in 
Opti-MEM + DMSO; tracer control: transfected cells in Opti-MEM + DMSO + Tracer K5 only), and were plotted 
alongside the raw mBRET values. The data with n = 3 biological replicates was first normalized and then fit using 
Sigmoidal, 4PL binding curve in Prism Software (version 8, GraphPad, La Jolla, CA, USA).
plasmids and reagents. ORFs used for Western blots were in a pHAGE-CMV-FLAG expression vector as 
previously  reported12.
Western blot.  Western blots were carried out as described  previously12. HEK293T cells were plated in 6-well 
format and incubated at 37 °C with 5%  CO2 for 12 h. Next, cells were transfected with 1.5 ug of plasmid per well 
for 24 h and treated with GW296115 (in DMSO). Samples were lysed using standard conditions of RIPA (10% 
glycerol, 50 mM Tris–HCL, 100 mM NaCl, 2 mM EDTA, 0.1% SDS, 1% Nonidet P-40, and 0.2% Sodium Deoxy-
cholate) supplemented with protease inhibitor cocktail (ThermoFisher Scientific, 78429), phosphatase inhibitor 
cocktail (ThermoFisher Scientific, 78426), NEM (Thermo Scientific, 23030), and Benzonase (Sigma, E1014). 
Lysis was carried out on ice over the course of 30 min and resultant lysates were centrifuged at 4 °C for 15 min 
at 21,000×g. Following normalization of protein concentration via BCA (Pierce, 23225), samples were denatured 
in NuPAGE LDS buffer (Invitrogen, NP0007) plus 1 mM DTT. Blots were imaged with a LiCor Odyssey imager, 
and then quantified using ImageStudio 5.2. Finally, ANOVA with multiple comparison was performed for quan-
titated blots using Prism 8.2.4. All antibodies used are listed in Table S3.
Data availability
All data generated or analyzed during this study are included in this published article (and its Supplementary 
Information File).
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